Iterum Therapeutics plc ITRM 深 滬
等待開盤 10-28 09:30:00 美东时间
0.6775
-0.017
-2.46%
華盛通- 最 高0.7099
- 今 開0.7099
- 成交量 94.94万股
- 最 低 0.6711
- 昨 收 0.6946
- 總市值 2710.00万
- 52周最高 3.02
- 市盈率 靜 --
- 換手率 2.37%
- 52周最低 0.6108
- 委 比 -84.33%
- 總股本 4000.00万
- 歷史最高 195.00
- 量 比 1.07
- 振 幅 5.59%
- 歷史最低 0.6108
- 每 手 1
- 風險率 0.44%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Iterum Therapeutics Announces $20M Share Offering
Iterum Therapeutics ( ($ITRM) ) has issued an update. On October 16, 2025, Iter...
10-17 05:49
Iterum Therapeutics to Present Data at IDWeek 2025
Iterum Therapeutics will present two posters at IDWeek 2025 in Atlanta on urinary tract infections (uUTIs), focusing on treatment failure risk and the in vitro activity of sulopenem. The company will also host a Learning Lounge discussing oral sulopenem for adult women. ORLYNVAH™, Iterum's oral penem antibiotic, is approved for treating uUTIs caused by resistant pathogens in adult women.
10-14 12:30
Iterum Therapeutics Provides Business Update
Iterum Therapeutics provided a business update on the launch of ORLYNVAH™ in the U.S. market, partnerships with EVERSANA, and progress in securing formulary coverage. The company also announced FDA clearance for its antimicrobial susceptibility test disc and updates on its patent portfolio in China and Mexico. Additionally, Iterum will participate in IDWeek 2025 with a presentation on urinary tract infections. The company expects its current cash...
09-19 12:00
Iterum Therapeutics Faces Shareholder Pushback on Key Proposals
Iterum Therapeutics ( ($ITRM) ) has provided an update. On September 10, 2025, ...
09-11 04:52
Iterum Therapeutics Faces Nasdaq Delisting Notice
The latest update is out from Iterum Therapeutics ( ($ITRM) ). On August 25, 20...
08-29 05:00
Iterum Therapeutics Launches New Antibiotic ORLYNVAH
Iterum Therapeutics ( ($ITRM) ) has issued an update. On August 20, 2025, Iteru...
08-20 20:45
Iterum Therapeutics Announces U.S. Commercial Launch Of ORLYNVAH Oral Tablets
Iterum Therapeutics plc (NASDAQ:ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today
08-20 20:02
Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.
Iterum Therapeutics has commercially launched ORLYNVAH™, the first FDA-approved oral penem antibiotic for treating uncomplicated urinary tract infections (uUTIs) in adult women caused by certain bacteria. The drug offers a critical new option as antibiotic resistance increases, with 57% of initial infections resistant to at least one antibiotic class. ORLYNVAH™, approved in October 2024, provides a much-needed alternative for patients with limite...
08-20 12:00
CORRECTION: Iterum Therapeutics Q2 Adj. EPS $(0.13) Misses $(0.11) Estimate. Cash And Equivalents Of $13M, Runway Into 2026
Iterum Therapeutics (NASDAQ:ITRM) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 43.48 percent increase over losses of $(0.23) per share
08-05 20:49
Iterum Therapeutics Non-GAAP EPS of -$0.13
Iterum Therapeutics press release (NASDAQ:ITRM): Q2 Non-GAAP EPS of -$0.13. Cash and cash equivalents were $13.0 million as of June 30, 2025. Based on Iterum’s current operating plan, Iterum expects t...
08-05 19:16
